{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108909","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.129507+00:00","generated_at":"2026-05-17T13:06:21.902135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb","bullets":["Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.","Initiated Phase 3 accelerated approval trial of IFx-2.0 with Keytruda in MCC under FDA SPA.","Raised $12.5M equity financing plus $3.0M from warrant exercise in June 2025; shares outstanding ~49.9M.","R&D expenses $4.9M (Q2 2025) vs $2.8M (Q2 2024); operating cash outflow ($10.9M) for 6 months.","Added to Russell 3000/2000 indices in June 2025; targets Phase 3 topline results 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108909","json":"https://secwatch.observer/filing/0000950170-25-108909.json","markdown":"https://secwatch.observer/filing/0000950170-25-108909.md","text":"https://secwatch.observer/filing/0000950170-25-108909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/0000950170-25-108909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:06:21.902135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}